Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Plasma Inhibitors of the Components of the Fibrinolytic Pathway in Man
Alan D. Schreiber, … , Allen P. Kaplan, K. Frank Austen
Alan D. Schreiber, … , Allen P. Kaplan, K. Frank Austen
Published June 1, 1973
Citation Information: J Clin Invest. 1973;52(6):1394-1401. https://doi.org/10.1172/JCI107312.
View: Text | PDF
Research Article

Plasma Inhibitors of the Components of the Fibrinolytic Pathway in Man

  • Text
  • PDF
Abstract

The effect of highly purified inhibitor of the first component of complement (CāINH), α2 macroglobulin (α2M), and α1 antitrypsin on the components of the fibrinolytic pathway in human plasma has been examined. CāINH was the only factor active upon the Hageman factor fragments functioning at the initial step of the fibrinolytic pathway, α2M was the only factor active against the plasminogen activator and the most active inhibitor of plasmin. The inhibition of plasmin by α2M appeared stoichiometric with one molecule of α2M inhibiting two molecules of plasmin. All three plasma inhibitors were active against plasmin.

Authors

Alan D. Schreiber, Allen P. Kaplan, K. Frank Austen

×

Full Text PDF

Download PDF (1.21 MB)

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts